1210 related articles for article (PubMed ID: 29116684)
21. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
[TBL] [Abstract][Full Text] [Related]
22. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
Sacks-Davis R; Doyle JS; Rauch A; Beguelin C; Pedrana AE; Matthews GV; Prins M; van der Valk M; Klein MB; Saeed S; Lacombe K; Chkhartishvili N; Altice FL; Hellard ME
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25051. PubMed ID: 29633559
[TBL] [Abstract][Full Text] [Related]
23. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
[TBL] [Abstract][Full Text] [Related]
24. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
Pol S; Parlati L
Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
[TBL] [Abstract][Full Text] [Related]
26. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?
Makarenko I; Artenie A; Hoj S; Minoyan N; Jacka B; Zang G; Barlett G; Jutras-Aswad D; Martel-Laferriere V; Bruneau J
Int J Drug Policy; 2019 Oct; 72():69-76. PubMed ID: 31010749
[TBL] [Abstract][Full Text] [Related]
27. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
[TBL] [Abstract][Full Text] [Related]
28. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
29. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
30. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
31. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
32. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
33. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
34. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
35. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.
Walsh N; Maher L
Curr Opin HIV AIDS; 2012 Jul; 7(4):339-44. PubMed ID: 22498482
[TBL] [Abstract][Full Text] [Related]
36. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.
Skaathun B; Borquez A; Rivero-Juarez A; Mehta SR; Tellez F; Castaño-Carracedo M; Merino D; Palacios R; Macías J; Rivero A; Martin NK
BMC Infect Dis; 2020 Aug; 20(1):588. PubMed ID: 32770955
[TBL] [Abstract][Full Text] [Related]
37. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
[TBL] [Abstract][Full Text] [Related]
38. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
39. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
40. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
Yazdani K; Dolguikh K; Zhang W; Shayegi-Nik S; Ly J; Cooper S; Trigg J; Bartlett S; Barrios R; Montaner JSG; Salters K
PLoS One; 2022; 17(3):e0265811. PubMed ID: 35320316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]